Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs
| dc.contributor.author | G Almutary, Abdulmajeed | |
| dc.contributor.author | A Almatroodi,Saleh | |
| dc.contributor.author | M Alnuqaydan, Abdullah | |
| dc.contributor.author | ETAL.. | |
| dc.date.accessioned | 2024-11-15T07:49:42Z | |
| dc.date.available | 2024-11-15T07:49:42Z | |
| dc.date.issued | 2023-01-18 | |
| dc.description | In the drug development process, systemic availability, off-target outcomes, and reduced efficacy comprise the main challenges for the successful clinical prediction of candidate drugs [1]. This situation highlights the need for superior preclinical tools so that intestinal function can be modelled [2]. For drug administration, oral delivery is the most common route, and in addition to absorption and metabolism, an appropriate location for specific substances, namely, nonsteroidal anti-inflammatory drugs (NSAIDs) and other therapeutic compounds, is directly provided by the intestine [3,4]. It also functions as an organ for studying interactions between drugs [5,6]. Animal models are often used to determine the toxicity and efficacy of drugs. However, species differences lead to a disparity in translating results to clinical settings [7]. | |
| dc.description.abstract | Physiological barrier function is very difficult to replicate in vitro. This situation leads to poor prediction of candidate drugs in the drug development process due to the lack of preclinical modelling for intestinal function. By using 3D bioprinting, we generated a colitis-like condition model that can evaluate the barrier function of albumin nanoencapsulated anti-inflammatory drugs. Histological characterization demonstrated the manifestation of the disease in 3D-bioprinted Caco-2 and HT-29 constructs. A comparison of proliferation rates in 2D monolayer and 3D-bioprinted models was also carried out. This model is compatible with currently available preclinical assays and can be implemented as an effective tool for efficacy and toxicity prediction in drug development. Keywords 3D bioprinting; colitis 3D model; drug prediction; barrier function; albumin nanoparticles; Roxadustat; CAPE | en |
| dc.identifier.citation | Almutary, A. G., Alnuqaydan, A. M., Almatroodi, S. A., Bakshi, H. A., Chellappan, D. K., & Tambuwala, M. M. (2023). Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs. Biomimetics, 8(1), 41. | |
| dc.identifier.doi | https://doi.org/10.3390/biomimetics8010041 | |
| dc.identifier.uri | https://repository.adu.ac.ae/handle/1/7037 | |
| dc.language.iso | en | |
| dc.publisher | MDPI | |
| dc.title | Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs | |
| dc.type | Article |